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Gender- and sex- related differences represent a new frontier towards patient-tailored medicine, taking into account that
theoretically every medical specialty can be influenced by both of them. Sex hormones define the differences between
males and females, and the different endocrine environment promoted by estrogens, progesterone, testosterone, and their
precursors might influence both human physiology and pathophysiology. With the term Gender we refer, instead, to behaviors,
roles, expectations, and activities carried out by the individual in society. In other words, “gender” refers to a sociocultural
sphere of the individual, whereas “sex” only defines the biological sex. In the last decade, increasing attention has been paid to
understand the influence that gender can have on both the human physiology and pathogenesis of diseases. Even the clinical
response to therapy may be influenced by sex hormones and gender, but further research is needed to investigate and clarify
how they can affect the human pathophysiology. The path to a tailored medicine in which every patient is able to receive early
diagnosis, risk assessments, and optimal treatments cannot exclude the importance of gender. In this review, we have focused
our attention on the involvement of sex hormones and gender on different endocrine diseases.
1. Sex Hormones in Endocrine
Gender-Related Differences
1.1. Introduction. Sex and gender intersect with other bio-
logical and social variables to produce between- or within-
group differences [1]. Those factors may reveal subgroup
differences among women and among men that would
have been obscured by using only gender or sex as a var-
iable. Accounting for differences in socioeconomic status,
for example, may reveal unexpected differences between
women and men that cannot be explained by gender or
socioeconomic status alone, such as women of high socioeco-
nomic status having health outcomes similar to those of men
of low socioeconomic status [2]. Understanding how factors
interrelate with sex or gender is important in explaining or
predicting differences in health outcomes and determining
user needs [3]. Among the medical disciplines, endocrinol-
ogy is probably the one that most falls in issues concerning
gender medicine. The hormones, in fact, determine sex, male
or female, but it is now clear that the epidemiology, the
clinical manifestations, the natural history of diseases, and
the response to therapy can be very different in both sexes
as well as because of the differences closely linked to the hor-
monal structure to the influence of social, economic, and cul-
tural factors, which contribute to ensuring that men and
women have important differences in health [4].
The interactions between sex and gender characteristics
are supposed to affect molecular and cellular processes and
clinical characteristics as well as health and disease outcomes
[5]. Nevertheless, evidence concerning how they interact is
scarce and requires a multidisciplinary approach. In this
manuscript, we focused our attention on the sex and gender
differences in endocrine pathophysiology. What makes
females different from males is essentially represented by
sex hormones and, in fact, the attention of scientific literature
has been, and continues to be, an understanding of the bio-
logical mechanisms activated by sex hormones that underlie
their pathophysiological diversities [6, 7]. Our attention has
focused on the effects that not only sex as hormones but also
gender can have in explaining differences in the human
Hindawi
International Journal of Endocrinology
Volume 2018, Article ID 4847376, 11 pages
https://doi.org/10.1155/2018/4847376
endocrine system. Conditions such as thyroid disease, diabe-
tes mellitus, osteoporosis, GH/IGF I axis diseases, obesity,
and sarcopenia clearly present gender differences [8–15].
Energy metabolism is also gender-specific, being greatly
influenced by estrogen, both at rest and during exercise
[16–18]. These hormones have also a considerable effect on
the pathogenesis of autoimmune endocrine diseases, as sug-
gested by their different prevalence, often significantly higher
in women than in men [19].
Finally, there are sex and gender differences which also
affect response to therapies, in terms of dose response, effi-
cacy, and appearance of adverse events, although these
aspects need to be further explored [20–28].
1.2. Gender-Related Differences in the Endocrine System.
Gender-specific medicine is a complex and intriguing chal-
lenge for the future of all medical specialties. Hormones rep-
resent what makes females different from males. Generally,
females and males have the same hormones (i.e., estrogens,
progesterone, and testosterone), but their production sites,
their blood concentrations, and their interactions with differ-
ent organs, systems, and apparatus are different [29]. Males
produce predominantly testosterone from the testes in a
relatively constant daily amount according to a circadian
profile. Small amounts of estrogens and progesterone are
produced by the testes and the adrenal glands or are pro-
duced in the peripheral tissues, such as adipose tissue or liver,
by the conversion of other precursor hormones [30]. In con-
trast, females mainly produce estrogens and progesterone
from the ovaries in a cyclical pattern, while a small amount
of testosterone (T) is produced by the ovaries and adrenal
glands. The levels of female sexual steroids follow a specific
and oscillating profile, due to a complex interaction between
the pituitary gland and the ovary [31–33]. Female and male
sexual steroids modulate in a different way, for example,
the distribution of body fat mass and fluids, the maintenance
of muscle and bone mass, the hepatic synthesis of numerous
enzymes (cytochrome P450 family enzymes), the synthesis of
triglycerides and HDL, and glucose metabolism. As a conse-
quence, in addition to the typical differences of sex directly
induced by hormones, we also have to consider the drug
peripheral distribution and transformation pathways, espe-
cially hepatic and renal, which may be responsible for their
reduced or increased efficacy as well as of the appearance of
adverse reactions, for example due to their inappropriate
doses or ways of administration. Moreover, socioeconomic
and cultural contexts may represent additional confounding
factors being able to influence the epidemiological character-
istics of diseases, the approach, and the response to specific
therapeutic treatments [9, 10, 13, 15].
1.3. Gender-Related Differences in Thyroid Disease. Thyroid
diseases are 5 to 8 times more common in females than in
males [34, 35]. Such data can be considered not only for
clinical and/or subclinical hypothyroidism and hyperthy-
roidism and for nodular thyroid diseases but also for auto-
immune conditions, such as Hashimoto’s thyroiditis and
Graves’ disease [36, 37]. It can be hypothesized that female
sex hormones (i.e., estrogens and progesterone) and their
particular patterns may be involved in explaining the higher
prevalence of thyroid diseases in females [37–39]. Differenti-
ated thyroid carcinoma (DTC), the most common endocrine
neoplasm, is also more common in women than in men, but
evidence regarding gender-related differences is scant [40].
According to recent data, the age-adjusted incidence ratio
of thyroid cancer in 2013 was 21.61/100,000 women and
7.26/100,000 men, for a female-to-male ratio of almost 3 : 1.
However, because of differences between sexes in thyroid
cancer peak age incidence, the female-to-male ratio is higher
during the reproductive period (4.1 : 1 at ages 20–49 years)
and steadily decreases with advancing age (1.38 : 1 at
ages≥ 75 years). Furthermore, females have a better survival
rate than age-matched males. Therefore, thyroid cancer is
more common in females but is more aggressive in males
[41, 42]. Pathophysiological reasons explaining this differ-
ence are unknown, but it has been proposed that estrogens
may play a fundamental role. This hypothesis is supported
by evidence that thyroid cancer has a higher incidence in fer-
tile women [43]. A causal role for the number of children, age
at first pregnancy, age at onset of menopause, and hysterec-
tomy has also been suggested [44]. According to a recent
meta-analysis, women with children have an increased risk
of thyroid cancer compared to nulliparous women (Relative
Risk 1.09, CI 1.03–1.15), but a linear relationship between
the number of children and the increased risk has not been
proven [40]. Nevertheless, the recent guidelines published
by the American Association of Clinical Endocrinologists
and the American College of Endocrinologists in 2015 sug-
gest that clinical trials do not support the role of estrogens
as a risk factor for the development of thyroid cancer at pres-
ent [45]. Female sex, together with the absence of lymph
node metastases, and the American Thyroid Association
(ATA) pediatric risk stratification system remained factors
related to better outcomes in pediatric DTC, even in longer
periods of observation (i.e., 32 years). Furthermore, girls with
no lymph node metastasis at diagnosis and those classified as
low risk by the ATA pediatric risk stratification system were
more likely to have no evidence of disease within the first
year compared to boys [46]. Regarding the therapeutic
aspects, gender does not affect the function of salivary glands
in patients affected by thyroid cancer undergoing first
attempt of radioactive iodine therapy [47].
1.4. Gender-Related Differences and Diabetes Mellitus.
Recently, it has been observed that diabetes mellitus may also
have some gender-specific peculiarities; some data highlight
that women have longer-term illness and higher body mass
index (BMI) compared to men [14]. In women, diabetes mel-
litus appears to be less controlled considering each metabolic
parameter. Italian data from annals published by Associa-
zione Medici Diabetologi (AMD), the Italian association of
diabetologists, showed that diabetic women had 14% higher
chance of having HbA1c> 9% regardless of insulin therapy,
42% more likely to have low-density lipoprotein (LDL) cho-
lesterol> 130mg/dL irrespective of statin therapy, and 50%
greater chance of having BMI> 30 kg/m2 [48, 49]. These data
seem to be partially confirmed in type 1 diabetic patients, in
whom women showed worse metabolic control and men
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had higher blood pressure [13]. Furthermore, diabetic
women, regardless of menopausal state, present significantly
higher risk of ischemic cardiomyopathy than diabetic men.
Diabetic women also have a worse prognosis after myocar-
dial infarction and a higher mortality rate from cardiovascu-
lar disease than diabetic men [50, 51]. A Canadian study
showed that long-term statin therapy reduces total and car-
diovascular mortality after myocardial infarction, and this
effect is pronounced over time in both sexes. However, this
risk reduction is lower in women than in men, suggesting a
gender-specific model of therapy response [25]. Regarding
the metabolic aspect, women show a different behavior in
their insulin response compared to men. In fact, the suscep-
tibility to develop insulin resistance and the insulin response
to stimuli that physiologically improve or compromise insu-
lin sensitivity are different in the two sexes [52]. Women
show a tendency to have lower insulin sensitivity than their
male counterpart but increase their insulin response to main-
tain normoglycemia (Table 1) [53, 54]. It can suggest that
these differences in insulin action may explain that in predi-
abetic state women are more prone to develop impaired glu-
cose tolerance whereas their male counterparts are more
susceptible to develop impaired fasting glycemia [55, 56].
This gender-related physiology may underline the different
effects showed by a combined therapy with exenatide and
metformin which induced better therapeutic results in
women compared with men [57]. Interestingly, the difference
in sex affects the prevalence of diabetes that is reversed
according to the stage of reproductive life. There are more
diabetic men before the age of puberty, while there are more
diabetic women after the age of menopause and in old age
[55]. Recent evidence confirms higher prevalence of T2DM
in adolescent females than males associated with a greater
insulin resistance in girls than in boys during puberty.
Beyond puberty, T2DM is more common in middle aged
men; different patterns of fat accumulation providing with
a greater subcutaneous fat presence in women along with
better insulin sensitivity may represent possible reasons
[58]. The role of menopausal estrogen deficiency in the
increased risk of type 2 diabetes mellitus in menopausal
women has been extensively studied. It should be considered
that estrogens affect positively glucose homeostasis within a
physiological window and any change outside the physiolog-
ical range, such as menopause or oral contraceptives, repre-
sents a risk factor for insulin resistance [55, 56]. In diabetes
mellitus, women are at higher risk of experiencing hypogly-
cemia using insulin and for urinary tract and genital infection
using gliflozin drugs. As a result of the use of thiazolidine-
diones, the risk of bone fractures in postmenopausal women
increases [15]. Finally, recent studies have observed a marked
influence of socioeconomic and psychosocial aspects on gly-
cemic health control and a significant association between
sociodemographic profile and absolute control of T1DM risk
factors [59, 60]. Furthermore, T2DM women and men with
lower income and education level show poor food choice
revealing higher carbohydrate and lower fat intake. Consid-
ering the sex-related difference in insulin sensitivity, it is clear
how sociodemographic aspects may interact with biology
[61]. This association has been observed also in pregnant
woman [62]. Even in the prevention and management of ges-
tational diabetes mellitus, maternal income and education
may have a strong impact [63]. Keeping in mind that the
term “gender” refers to social and psychological differences
between men and women, further studies are warranted to
clarify the influence of gender on glycemic health and the
interactions with biological distinctions [4].
1.5. Gender-Related Differences and Osteoporosis. A large
part of clinical evidence is based on trials on male subjects,
creating the so-called male-bias evidence-based medicine.
Nevertheless, scientific studies on osteoporosis represent an
exception to male-bias evidence-based medicine. In fact,
osteoporosis has always been considered a typical female dis-
ease, although it is also common in males. As a consequence,
osteoporosis is most commonly investigated in women, espe-
cially after menopause, and it is rarely considered in men,
who also present significant risk factors [64]. Indeed, a lower
proportion of men at high risk of fracture are treated than
women at high risk [65]. Men also tend to have worse out-
comes after fracture than women; they are twice as likely to
die after hip fracture as women [66].
Interestingly, the Epidemiologic Study on the Prevalence
of Osteoporosis (ESOPO), the main Italian epidemiologic
study on osteoporosis, was conducted on 11,011 females
and 4981 males and showed that in females the prevalence
of osteoporosis was about 18.5%, while in males it was about
10%. Similarly, the prevalence of osteopenia was 44.7% and
36%, respectively. The presence of bone fracture was con-
firmed in 17.6% of females and in 17.5% of males. There-
after, mortality was 2–3 times higher in males suffering
with femur fracture than in females. These data suggest
that bone health and status should be carefully evaluated
Table 1: Endocrine roles of estrogens in the human body.
Thyroid
Increase TBG; decrease free fraction of thyroxine
[129]; downregulation of the thyroid somatostatin
receptor (SSTR) [11, 129]
Glucose
metabolism
Increase insulin sensitivity; protect
pancreatic β-cells [130]
Bone
Inhibit generation and activity of osteoclasts;
upregulation of osteoprotegerin; decrease T cell
activation; decrease IFN-γ release by T cells;
increase intestinal calcium absorption [8]
Muscle
Increase levels of proanabolic factors; reduce
muscle inflammation; decrease muscle damage;
increase postexercise muscle satellite cell
activation and proliferation; increase intrinsic
contractile muscle function [109, 110]
GH/IGF-1 axis
Decrease hepatic IGF-1 production;
downregulation of the thyroid
somatostatin receptor (SSTR) [11]
Adipose tissue
Increase gynoid fat deposition [88];
decrease postprandial fatty acid oxidation
[95, 96]; increase fat oxidation during
submaximal exercise [16, 98]; decrease
energy intake; increase energy expenditure;
reduce tissue inflammation [130]
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even in elderly males [67]. The physiopathology of osteopo-
rosis is clearly sex-specific. Males tend to have higher bone
mineral density and bone content and reach it at an older
age than females, while females tend to lose bone density at
a younger age and at a faster rate than males and also have
higher bone reabsorption markers [68]. Later in life, the pro-
duction of sex hormones decreases earlier and more mark-
edly in females. This aspect can be the basis of the presence
of fractures about 5–10 years earlier in females than in males
[69]. Indeed, estrogens play a crucial role in bone health in
both sexes, and their deficiency is supposed to be the main
cause of bone loss in postmenopausal females and in elderly
males, in particular for cortical bone [70]. Estrogens inhibit
generation and activity of osteoclasts through an upregula-
tion of osteoprotegerin, decrease T-cell activation and conse-
quently also interferon-γ release by T-cells, and increase
intestinal calcium absorption [71, 72]. In females, estrogen
decline is abrupt at the beginning of the menopausal period,
while in males the decline in T and, consequently, in estro-
gen, is low and constant with aging, so it is clear how sex dif-
ferences in osteoporosis exist. An increase in both bone
formation markers and bone reabsorptionmarkers have been
observed in postmenopausal females, suggesting an increase
in the rate of bone remodeling as confirmed by histomorpho-
metry. In elderly males, biochemical markers of bone degra-
dation seem to increase but bone formation markers appear
to be stable or decreased, therefore suggesting a low bone
remodeling rate (Table 1) [8]. Furthermore, an alteration of
the inflammatory state of the bone has been demonstrated
to be more pronounced in postmenopausal females than in
older males, thus negatively affecting bone health [73, 74].
According to the underlying causes, osteoporosis may
be primary or secondary. Prevalence of secondary osteopo-
rosis in females reaches up to 20–40% of cases, while this
value rises to 65% in males [75]. Scientific studies on oste-
oporosis therapy have mostly focused their attention on
females, then considering their results applicable to males.
However, it seems that females are more prone to suffer
from side effects associated with bisphosphonates. The
higher relative cases of atypical bone fractures in women than
in men are not entirely related to an increased use of bispho-
sphonates but also to sex per se, which should be considered
a risk factor for atypical fracture [76]. Some oncological dis-
eases (breast and prostate cancer) can induce modification of
the bone metabolism, also aggravated by the use of anticancer
therapies both in women and in men. Hormone therapy
(aromatase inhibitors such as anastrozole, letrozole and exe-
mestane, LHRH analogs, bicalutamide, and abiraterone) and
chemotherapies can induce a greater bone resorption com-
pared to its synthesis, creating a net effect of loss of bone
mass, a reduction of resistance and a consequent increase in
bone fractures in both women and men, even in the absence
of trauma. Global bone health can also be compromised by
high doses of cortisone associated with certain treatments
and pathological changes related to oncology in itself (early
menopause in women and hypogonadism in men).
1.6. Gender-Related Differences and the Growth Hormone/
Insulin Growth Factor 1 Axis. The clinical evidence supports
the effects of estrogens on the growth hormone (GH)/insulin
growth factor 1 (IGF-1) axis [77]. In fact, several studies have
shown that estrogens inhibit GH-stimulated liver production
of IGF-1 [77, 78]. In turn, GH levels rise to overcome the
inhibitory effects of estrogen. It has been observed that the
levels of GH are higher in females than in males, and they
fluctuate according to the phase of the menstrual cycle and
depending on the menopausal state [79]. Moreover, during
the first trimester of pregnancy, estrogen levels increase and
consequently IGF-1 levels decrease in the absence of any
change in GH levels. IGF-1 levels increase from the begin-
ning of the second quarter due to the gradual increase in pla-
cental GH [80]. The effect of estrogens on the GH/IGF-1 axis
is also noteworthy even in pathologies characterized by defi-
ciency or excess of GH.
Females suffering from GH deficiency require a much
higher dose of recombinant GH (rhGH) than males. Women
taking oral estrogens need a higher dose of rhGH than those
taking transdermal estrogens [81, 82]. It can be hypothesized
that the inhibitory action of oral estrogens on the metabolic
effect of GH is mediated by stimulation of cytokine 2 sup-
pressor expression (SOCS-2), which in turn inhibits the
phosphorylation of Janus kinase 2 (JAK2), a key passage in
the signaling path JAK2/signal transducer and activator of
transcription 5 (STAT5) activated by GH. The inhibition of
enzymatic function of JAK prevents GH from exerting its
metabolic effects, including the hepatic synthesis of IGF-1
[83]. Indeed, stimulated JAK2 adds a phosphate group to
specific tyrosine residues on the cytoplasmic domain of the
GH receptor. Therefore, using its Src homology 2 (SH2)
domain, STAT5 binds to these phosphorylated tyrosine resi-
dues [84]. The bound STAT5 is phosphorylated by JAK2 to
specific tyrosine residues and is ready to form homodimers
or heterodimers to act as a transcription factor (Table 1)
[11]. Females suffering from acromegaly show lower IGF-1
levels than males who suffer from the same condition. It is
interesting to highlight that in some specific acromegalic
females, IGF-1 levels decrease during the first trimester of
pregnancy [85]. A possible explanation could be the physio-
logical increase in estrogen levels and their subsequent inhibi-
tion of IGF-1production in the liver [84]. Thismechanismcan
be considered as a possible reason for the improvement of the
clinical conditions of acromegalic females during this period
[84]. Acromegaly has also shown some clinical differences
between the sexes, as specificmetabolic alterations of the acro-
megaly are sex-specific. Acromegalic females are more prone
to suffer from insulin resistance andmetabolic syndrome than
males, even in the absence of significant differences in blood
glucose and/or glycated hemoglobin (HbA1c). In addition, a
higher prevalence of metabolic syndrome, visceral obesity,
anddiabetesmellituswasobserved inpostmenopausal females
compared to premenopausal females and males [12]. It is
interesting to note that the administration of rhGHoften leads
to hypothyroidism throughboth central andperipheralmech-
anisms; in particular, rhGH appears to decrease the TSH level
by increasing IGF-1 [86]. In fact, IGF-1 seems to be involved in
thedirect stimulationof somatostatinmRNAsynthesis and, in
turn, somatostatin inhibits TSH secretion [87]. This process
has not always been observed in females, and it seems that
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gonadal hormones play a fundamental role due to their inhi-
bition of IGF-1 secretion, as mentioned above, and their
downregulation of the thyroid somatostatin receptor (SSTR)
by estrogen. SSTRs 1, 3, 4, and 5 are highly expressed in nor-
mal thyroid tissue, and estrogen has a differential effect on
distinct SSTs, subregulating the expression of SSTRs 1 and
5 (Table 1) [11].
1.7. Gender-Related Differences and Obesity. Females and
males showed marked differences in the prevalence of obe-
sity, in fat deposition patterns, and in fat metabolism.
Females generally have a higher percentage of fat mass and
are more likely to deposit fat subcutaneously and on their
lower extremities whilemen aremore likely to deposit visceral
fat in the abdominal region [88]. Adipose tissue increases with
puberty and early pregnancy, suggesting that gonadal steroids
can influence body fat. Following menopause-induced estro-
gen loss, a shift towards visceral adiposity occurs, which is sen-
sitive to estrogen therapy [89]. These facts highlight the
importance of estrogens in subcutaneous fat accumulation.
At cellular level, estrogen function is mediated by alpha
(ERα) and beta (ERβ) receptors although recent research
observed nongenomic and rapid effects of steroid hormones
throughout cytosolic or plasma membrane-associated recep-
tors.BothERαandERβare expressed in subcutaneousandvis-
ceral adipose tissue; however, it seems that ERα plays a pivotal
role in sexual dimorphismof fat distribution. Female andmale
mice that lack ERα have visceral obesity with severe insulin
resistance. Furthermore, estrogens seem to promote and
maintain the typical female type of fat distribution by affecting
lipolysis,which is controlled inhumansprimarilyby theaction
of β-adrenergic receptors (lipolytic) and α2A-adrenergic
receptors (antilipolytic). Estrogens increase the number of
antilipolytic α2A-adrenergic receptors in subcutaneous adi-
pocytes; in contrast, no effect of estrogens on α2A-adrenergic
receptor mRNA expression was observed in adipocytes from
the intra-abdominal fat depotwhere ahighα2A/β ratio ispres-
ent [90]. In premenopausal women, α2A to β1–2-adrenergic
receptor ratio is increased in subcutaneous fat tissue compared
to men and to postmenopausal women thus decreasing the
lipolytic response to adrenergic and noradrenergic stimuli.
This balance of adrenergic receptors is reversed in the visceral
depot of premenopausal women, favoring lipolysis of visceral
fat and it accounts for deposition of fat in subcutaneous
adipocytes in premenopausal women. In postmenopausal
females, adrenergic receptor ratio is reversed thus poten-
tially explaining the preferential accumulation of fat in
the visceral depot. Therefore, at the adipocyte levels, estro-
gens and their receptors may have the capacity to increase
the accumulation of fat cells in the subcutaneous deposit
and to inhibit it in the visceral deposit [91].
This pattern of fat accrual affords protection from the
negative consequences associated with obesity and the
metabolic syndrome in premenopausal females. However,
after menopause, the decrease of estrogen secretion leads
to fat deposition and accrual shift in favor of the visceral
depot. This shift is accompanied by a parallel increase in
metabolic risk similar to that seen in males. Estrogen appears
to protect against obesity also through the suppression of
appetite, as observed during the periovulatory phase of the
menstrual cycle, and by increasing energy expenditure [91].
T exerts its antiobesity effect by activation of the androgen
receptor (AR) pathway on mesenchymal stem cells, sup-
pressing the adipogenic line cells and favoring the myogenic
line. Furthermore, T increases lipolysis and the number of β-
adrenergic receptors on the membranes of adipocytes and
inhibits triglyceride uptake and lipoprotein lipase activity.
Nevertheless, in females, hyperandrogenism positively cor-
related with visceral fat, waist circumferences, and insulin
resistance. Androgen excess may induce these effects through
both central and peripheral mechanisms. Failure to activate
leptin with consequent blockage of brown adipose tissue
thermogenesis and reduced expression of hypothalamic
proopiomelanocortin may represent important central
control mechanisms. Peripherally, the interaction with
estradiol may explain the different effects of T on women
metabolism [92]. Additionally, cross-sex hormonal therapy
of male-to-female transsexuals increases the amount of sub-
cutaneous adipose tissue accrual relative to intra-abdominal
adipose tissue whereas more masculine body fat distribution
with a lower hip circumference has been observed in trans
males [93].
Finally, a sex-specific fat deposition pattern represents
a physiological condition in which sex hormones play a
pivotal role. Nevertheless, in both sexes, the presence of
normal sex hormone levels is protective against obesity,
and a tendency to increase central obesity is observed with
a decrease in sex steroid hormones, as it happens with old
age or gonadectomy [94].
Estrogens also affect fuel metabolism by reducing post-
prandial fatty acid oxidation, leading to an increase in body
fat which may account for the increased fat mass observed
in women compared to men and the increased fat early in
pregnancy (Table 1) [95]. Interestingly, O'Sullivan et al.
showed that basal lipid oxidation was reduced in pregnant
and nonpregnant women compared to postmenopausal
women, and postprandial lipid oxidation was reduced in
pregnancy compared to nonpregnant healthy women, who
in turn have lower postprandial lipid oxidation than post-
menopausal women (Table 1) [96]. A possible explanation
for this efficient fat storage of energy in female puberty and
in early pregnancy is the obvious biological advantage in
preparation for fertility, fetal development, and lactation
[95]. Otherwise, women show a greater reliance on fat oxi-
dation than men during submaximal exercise, showing a
higher maximum fat oxidation rate and a fat oxidation curve
which tends to be shifted toward higher exercise intensities
[97]. It seems likely that both genomic and nongenomic
actions of estrogens may play a role in explaining these obser-
vations. In particular, estrogens mainly act through estrogen
receptor-alpha in the skeletal muscle to stimulate the geno-
mic expression of proteins to increase the availability of long
chain fatty acids (LCFA) improving adipocyte lipolysis and
increasing intramyocellular lipid storage. Following on,
estrogens affect fuel metabolism during exercise by nonge-
nomic means to increase the activation of 5′ adenosine
monophosphate-activated protein kinase (AMPK) [16, 98].
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1.8. Gender-Related Differences in Sarcopenia. Sarcopenia is
an age-related syndrome defined by the loss of muscle mass
and strength and/or performance, often associated with
chronic diseases, obesity, and prolonged immobilization.
However, it also represents a physiological condition of aging
[99, 100]. The etiology of sarcopenia is multifactorial but
still poorly understood. A decrease of anabolic hormones
plays a role in the development and in the maintenance of
sarcopenia [101]. In particular, the decrease in T appears to
be crucial in elderly males, and the administration of T in
hypogonadal subjects may be extremely helpful in limiting
the loss of muscle mass and strength (Table 2). Indeed, T
administration is able to significantly increase muscle mass
and decrease fat mass also in eugonadal males, even in total
absence of any training stimulus [102–104]. T is also of par-
amount importance in supporting adaptation to strength
training. Indeed, in evaluating sarcopenia, three aspects
should be carefully evaluated: physical exercise, nutrition,
and hormonal homeostasis [101]. In particular, strength
training represents the form of physical exercise which has
the greater positive impact in limiting loss of muscle mass.
However, it has been observed that the adaptive process to
strength training requires adequate serum level of T [105].
Therefore, in the presence of overt hypogonadism, strength
training results to be almost useless and ineffective in the
therapy of sarcopenia (Table 2). Aside these effects, the pos-
itive effects of T on erythropoiesis and on mood should be
also considered as they may support elderly men to follow a
consistent training schedule [106–108].
In postmenopausal women, evidence regarding the effect
of abrupt decrease of estrogens on muscle mass and strength
and eventually the impact of hormonal replacement therapy
(HRT) is scarce. During menopause, females show a marked
decrease in muscle mass and strength, while in males this loss
is constant and takes place more slowly. However, this is not
shown in women undergoing HRT [109]. A meta-analysis
showed that strength was significantly greater in women on
HRT. The effect sizes (ESs) were calculated as the standard-
ized mean difference and amounted to 0.23, equating to
women on HRT being ∼5% stronger. Nevertheless, effect
sizes tended to be greater (∼0.45) when only randomized;
controlled trials were considered or when strength was nor-
malized for muscle size, indicating that estrogens affect pos-
itively muscle strength and contractile properties of muscle
tissue [110]. Estrogens appear to act via several mechanisms,
such as increased levels of proanabolic factors, reduced sys-
temic and muscle inflammation, decreased muscle damage,
and augmented postexercise muscle satellite cell activation
and proliferation. Furthermore, estrogens also seem to
improve intrinsic contractile muscle function altering myo-
sin functions, as reported by increased strength normalized
to muscle size (Table 1) [109, 111]. A recent study with
monozygotic twin pairs showed that thigh muscle cross-
sectional area tended to be larger, relative muscle area
greater, and relative fat area smaller in HRT users than in
their sisters. In particular, tibolone administration, a tissue-
specific compound with estrogenic, progestogenic, and weak
androgenic activities [112], increased muscle cross-sectional
area [113]. Tibolone showed promising effects, increasing
significantly handgrip strength compared to placebo in post-
menopausal women and improving markedly isometric knee
extension strength, adjusted for BMI [114]. In a cross-
sectional study, mean knee extensor strength was higher in
women taking tibolone or estrogen compared to no HRT
[115]. Following on, tibolone seems to affect body composi-
tion, increasing lean mass and decreasing total body fat mass
[112, 116–118]. Thus, the lower rate of falling in the tibolone
group observed by Cummings et al. might reflect an andro-
genic effect on muscular function [119].
1.9. Gender-Related Differences in Drug Response. Most sci-
entific studies on drug response have been performed on
male subjects and the results have been considered valid also
for females, assuming that sex did not affect the outcome
(Yentl syndrome) [120, 121]. However, it should be noted
that in 2005 eight out of ten prescription drugs were with-
drawn from the US market because of women’s health issues
[122]. Recently, the NHS andMedical Research Council have
evaluated the causes and effects of women’s sociodemo-
graphic exclusions from clinical trials. Therefore, the use of
statins and nonsteroidal anti-inflammatory drugs (NSAIDs)
has been investigated. These drugs demonstrated a marked
difference in the sex of subjects included in the trials. Studies
on NSAIDs have reflected the population in which they were
used, while those for statins did not and only 16% of women
were included in trials compared with 45% who were using
statins [123]. The therapeutic response may be different
Table 2: Endocrine roles of T in the human body.
Sexual function Increase libido and erectile function [131]
Glucose
metabolism
Increased insulin sensitivity [132, 133]
Bone
Increased bone mineral density;
reduction in bone resorption markers
Decrease of osteoblast apoptosis rate
Stimulation of osteoprogenitor cell
proliferation and of differentiation of
mature osteoblasts
Decrease of osteoclast formation and
bone resorption through an increased
production of osteoprotegerin [134–136]
Muscle
Increase in both cross-sectional area and
myonuclei number; increased muscle fiber
area via hyperplasia and hypertrophy;
increased muscle strength [101]
Haematopoietic
system
Stimulation of erythropoiesis directly and
erythropoietin synthesis in the kidney
Promotion of erythropoietic stem cell
differentiation and increased sensitivity
of erythroid progenitors to erythropoietin
[137, 138]
Adipose tissue
Commitment of pluripotent mesenchymal
cells into myogenic lineage; inhibition of
commitment of pluripotent mesenchymal
cells into adipocyte lineage and inhibition
of differentiation of subcutaneous
abdominal preadipocytes into adipocytes.
Net decrease in fat mass [101]
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between genders, and even if evidence is far from being con-
clusive, the existing data have to be considered and evaluated
[124]. Indeed, it is well known that cytochrome expression
may be a gender-specific mechanism involved in difference
in drug metabolism [125, 126]. Concerning lipid-lowering
drugs, it has been observed that women on atorvastatin had
more side effects (i.e., increased liver enzymes and myalgia)
than men. However, atorvastatin and rosuvastatin seemed
to have similar efficacy in both sexes [26]. On the contrary,
fenofibrate improved lipid profile more in women than in
men and reduced cardiovascular events by 30% in women
and 13% in men [27, 127]. In evaluating gender differences,
it should be considered that patients with lower income are
more likely to use generic drugs. The presence of different
excipients may affect drug response therapy according to
sex [128].
2. Conclusions
Sex- and gender-specific differences can be observed in sev-
eral endocrine diseases, but the majority of these aspects have
not been carefully assessed so far. However, evidence in the
scientific literature holds that sex and gender should always
be considered in every element of the disease, from the causes
to the treatment.
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